Vir Biotechnology and Gilead Partner on Solid Tumor T-Cell Therapies

  • Vir Biotechnology and Gilead Sciences have entered a multi-program collaboration to develop three novel PRO-XTEN® dual-masked T-cell engagers (TCEs) for solid tumors.
  • Gilead will have exclusive rights to develop and commercialize the TCEs, while Vir Biotechnology will receive up to $135 million in upfront and near-term preclinical milestone payments.
  • The deal includes a $90 million upfront payment, with $65 million in cash and a $25 million equity investment at a 30% premium.
  • Vir Biotechnology could receive up to $1.74 billion in additional development, regulatory, and commercial milestones, along with tiered royalties on net sales.

This collaboration underscores the growing focus on next-generation immunotherapies for solid tumors, an area with significant unmet medical needs. The deal validates Vir Biotechnology's PRO-XTEN® platform and positions Gilead to expand its oncology portfolio. The strategic partnership highlights the increasing importance of biotech collaborations in advancing complex cancer treatments.

Technical Feasibility
How Vir Biotechnology's PRO-XTEN® masking technology will perform in solid tumors, addressing current toxicity challenges.
Commercial Potential
Whether Gilead can successfully develop and commercialize the TCEs, given its growing oncology capabilities.
Financial Impact
The pace at which Vir Biotechnology realizes milestone payments and royalties, and how this affects its financial strategy.